Tokyo Tape
Sign in
← Otsuka Holdings

Quarterly report · Q1

4578.TEDINET S100QQZ3
Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥1.74T2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥380.3bn2022-01-01 → 2022-03-31Cons.Revenue IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Operating income¥20.7bn2022-01-01 → 2022-03-31Cons.Operating profit loss IFRS
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥173.0bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥31.0bn2022-01-01 → 2022-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥133.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.3bn2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥24.2bn2022-01-01 → 2022-03-31Cons.Profit loss IFRS
Total assets¥3.13Tat 2023-03-31Cons.Assets IFRS
Total assets¥3.10Tat 2022-12-31Cons.Assets IFRS
Total assets¥2.89Tat 2022-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥811.5bnat 2023-03-31Cons.Liabilities IFRS
Total liabilities¥840.3bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥2.10Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥2.05Tat 2021-12-31dCons.Equity IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.23Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.07Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥423.4bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥211.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥57.7bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.6bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥22.8bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.5bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥34.6bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥246.82022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥42.862022-01-01 → 2022-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥246.782022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥42.72022-01-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥42.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥33.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥9.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥13.0bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥11.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥72.7bn
—segment totalrevenue2023-01-01 → 2023-03-31¥458.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥9.7bn
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-01-01 → 2022-03-31¥39.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-01-01 → 2022-03-31¥30.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-01-01 → 2022-03-31¥4.1bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥11.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2022-01-01 → 2022-03-31−¥235m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥11.3bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥17.3bn
—segment totalrevenue2022-01-01 → 2022-03-31¥389.1bn
—segment totalrevenue external2022-01-01 → 2022-03-31¥380.3bn
—segment totalrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
—segment totalsegment profit2022-01-01 → 2022-03-31¥32.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 706
ItemContextValueUnit
Profit loss IFRSCurrentYTDDuration62663000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration33000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration20000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-6174000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration4125000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration40000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration33000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-6100000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration4178000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration56254000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration9766000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration-1000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration30000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration12346000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration7532000000JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration68599000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration17329000000JPY
Other comprehensive income IFRSPrior1YTDDuration62498000000JPY
Other comprehensive income IFRSCurrentYTDDuration21508000000JPY
Comprehensive income IFRSPrior1YTDDuration86677000000JPY
Comprehensive income IFRSCurrentYTDDuration84171000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration85041000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration83148000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration1636000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration1023000000JPY
Comprehensive income IFRSPrior1YTDDuration86677000000JPY
Comprehensive income IFRSCurrentYTDDuration84171000000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember81690000000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember506724000000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-45572000000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember1482197000000JPY
Equity IFRSPrior2YearInstant_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Equity IFRSPrior2YearInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember28632000000JPY
Cumulative effect of accounting change IFRSPrior2YearInstant_ShareCapitalIFRSMember－JPY
Cumulative effect of accounting change IFRSPrior2YearInstant_CapitalSurplusIFRSMember－JPY
Cumulative effect of accounting change IFRSPrior2YearInstant_TreasurySharesIFRSMember－JPY
Cumulative effect of accounting change IFRSPrior2YearInstant_RetainedEarningsIFRSMember-37000000JPY
Cumulative effect of accounting change IFRSPrior2YearInstant_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Cumulative effect of accounting change IFRSPrior2YearInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Restated balance IFRSPrior2YearInstant_ShareCapitalIFRSMember81690000000JPY
Restated balance IFRSPrior2YearInstant_CapitalSurplusIFRSMember506724000000JPY
Restated balance IFRSPrior2YearInstant_TreasurySharesIFRSMember-45572000000JPY
Restated balance IFRSPrior2YearInstant_RetainedEarningsIFRSMember1482160000000JPY
Restated balance IFRSPrior2YearInstant_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Restated balance IFRSPrior2YearInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember28632000000JPY
Profit loss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember23250000000JPY
Profit loss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass